Pharsight

Xeglyze is owned by Dr Reddys Labs Sa.

Xeglyze contains Abametapir.

Xeglyze has a total of 5 drug patents out of which 0 drug patents have expired.

Xeglyze was authorised for market use on 24 July, 2020.

Xeglyze is available in lotion;topical dosage forms.

Xeglyze can be used as topical treatment of head lice infestation in patients 6 months of age and older.

Drug patent challenges can be filed against Xeglyze from 2024-07-24.

The generics of Xeglyze are possible to be released after 17 December, 2034.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9839631	DR REDDYS LABS SA	Methods and compositions for controlling ectoparasites	Jul, 2024 (1 year, 3 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8212038	DR REDDYS LABS SA	Methods and compositions for controlling ectoparasites	Jul, 2024 (1 year, 3 months from now)
US9357783	DR REDDYS LABS SA	Methods and compositions for controlling ectoparasites	Jul, 2024 (1 year, 3 months from now)
US7812163	DR REDDYS LABS SA	Methods and compositions for controlling ectoparasites	Oct, 2026 (3 years from now)
US10292389	DR REDDYS LABS SA	Pediculicidal composition	Dec, 2034 (11 years from now)